
|Videos|August 26, 2021
Role of Second Generation FLT3 Inhibitors in AML
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery
3
Updates in Treatment of Unresectable Hepatocellular Carcinoma
4
Potential Benefits of GLP-1 Agonists in Reducing Chemotherapy-Related Toxicities in Breast Cancer
5










































































































































































































